-Andrew L Harris Researcher Activity Profile

Research Author Detailed Information 

Andrew L Harris Publication Rate By Year

Andrew L Harris has published 1 paper(s) in 1989, 1 paper(s) in 1993, 2 paper(s) in 1999, 1 paper(s) in 2000, 1 paper(s) in 2001, 2 paper(s) in 2005, 2 paper(s) in 2006, 20 paper(s) in 2007, 15 paper(s) in 2008, for a total of 45 research publications in total.

Andrew L Al Harris Author Information

LAST NAME: harris

FIRST NAME: Andrew L

INITIALS: al

AFFILIATION:

Papers

Andrew L Harris's Publication Record

1. Nature of Cx30-containing channels in the adult mouse mammary gland. Year Published: 2007
Department of Pharmacology and Physiology, New Jersey Medical School, UMDNJ, Newark, NJ 07103, USA. lockeda@umdnj.edu
2. c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer. Year Published: 2000
Department of Radiotherapy/Oncology, University Hospital of Iraklion, Crete, Greece. targ@her.forthnet.gr
3. Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Year Published: 2005
University Hospital of Leipzig, Department of Hematology and Oncology, D-04103 Leipzig, Germany. martin.raida@medizin.uni-leipzig.de
4. Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. Year Published: 2005
Department of Hematology/Oncology, University of Leipzig, 04103, Leipzig, Germany. martin.raida@medizin.uni-leipzig.de
5. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Year Published: 2006
Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
6. 2-aminoethoxydiphenyl borate directly inhibits channels composed of connexin26 and/or connexin32. Year Published: 2007
Department of Pharmacology, Zhongsan College of Medicine, Sun Yet-San University, Guangzhou China 510080. taol@mail.sysu.edu.cn
7. Ca2+-dependent inactivation of CaV1.2 channels prevents Gd3+ block: does Ca2+ block the pore of inactivated channels? Year Published: 2007
Department of Pharmacology and Physiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ 07103, USA.
8. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Year Published: 2007
Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK.
9. Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer. Year Published: 2007
Department of Surgery II, School of Medicine, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo 162-8666, Japan. t-kato@bd5.so-net.ne.jp
10. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Year Published: 2007
Tumor and Angiogenesis Research Group, Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece. targ@her.forthnet.gr
11. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Year Published: 2007
Growth Factor Group, Cancer Research-UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DS, UK, howard.mellor@imm.ox.ac.uk.
12. Activating transcription factor 4. Year Published: 2007
University of Stanford School of Medicine, Department of Radiation Oncology, CCSR-South, 269 Campus Drive, Stanford, CA 94305, USA.
13. Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer. Year Published: 2007
Department of Surgery II, School of Medicine, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo 162-8666, Japan. t-kato@bd5.so-net.ne.jp
14. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Year Published: 2007
Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
15. Temperature-Dependent Femtosecond Photoinduced Desorption in CO/Pd(111). Year Published: 2007
Chemistry Department, Brookhaven National Laboratory, Upton, New York 11973-5000.
16. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Year Published: 2006
Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
17. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Year Published: 2007
Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK.
18. Gap junction channel structure in the early 21st century: facts and fantasies. Year Published: 2007
Department of Cell Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA. yeager@scripps.edu
19. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Year Published: 2007
Growth Factor Group, Cancer Research-UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DS, UK.
20. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Year Published: 2007
Growth Factor Group, Cancer Research-UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DS, UK.
21. Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. Year Published: 2008
Harold Hopkins Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom.
22. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Year Published: 2001
ICRF Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.
23. Gap junction channel structure in the early 21st century: facts and fantasies. Year Published: 2007
Department of Cell Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA. yeager@scripps.edu
24. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Year Published: 2007
Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
25. Mobilization of endothelial progenitor cells into the circulation in burned patients. Year Published: 2008
Stem Cells and Immunotherapies, National Blood Service, NHS Blood and Transplant, Oxford, UK.
26. Temperature-dependent femtosecond photoinduced desorption in CO/Pd(111). Year Published: 2007
Chemistry Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA.
27. Mobilization of endothelial progenitor cells into the circulation in burned patients. Year Published: 2008
Stem Cells and Immunotherapies, National Blood Service, NHS Blood and Transplant, Oxford, UK.
28. Mobilization of endothelial progenitor cells into the circulation in burned patients. Year Published: 2008
Stem Cells and Immunotherapies, National Blood Service, NHS Blood and Transplant, Oxford, UK.
29. BNIP3 expression in endometrial cancer relates to active hypoxia inducible factor 1alpha pathway and prognosis. Year Published: 2008
Department of Pathology, Democritus University of Thrace, Alexandroupolis 68100, Greece. targ@her.forthnet.gr
30. Epidermal growth factor receptor in human breast cancer. Year Published: 1989
ICRF Clinical Oncology Unit, Churchill Hospital, Oxford, Great Britain.
31. Growth factors and angiogenesis in breast cancer. Year Published: 1993
Molecular Oncology Laboratory, John Radcliffe Hospital, Oxford, UK.
32. BHLHB2 controls Bdnf promoter 4 activity and neuronal excitability. Year Published: 2008
Section on Molecular Genetics, Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, USA.
33. Activating transcription factor 4. Year Published: 2007
University of Stanford School of Medicine, Department of Radiation Oncology, CCSR-South, 269 Campus Drive, Stanford, CA 94305, USA. kameri@stanford.edu
34. BNIP3 expression in endometrial cancer relates to active hypoxia inducible factor 1alpha pathway and prognosis. Year Published: 2008
Department of Pathology, Democritus University of Thrace, Alexandroupolis 68100, Greece. targ@her.forthnet.gr
35. Is primary chemotherapy useful for all patients with primary invasive breast cancer? Year Published: 1999
Département de Médecine Oncologique, Institut Curie, Paris, France.
36. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Year Published: 1999
ICRF Molecular Oncology Laboratory, John Radcliffe Hospital, Oxford, UK.
37. BHLHB2 controls Bdnf promoter 4 activity and neuronal excitability. Year Published: 2008
Section on Molecular Genetics, Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, USA.
38. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Year Published: 2008
Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU, UK. ernyu2002@yahoo.com.sg.
39. Breast tumour angiogenesis. Year Published: 2008
Pathology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, 3002, Australia. stephen.fox@petermac.org.
40. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Year Published: 2008
Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.
41. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Year Published: 2008
Genomics Group, Wellcome Trust Centre for Human Genetics, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Oxford, United Kingdom.
42. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Year Published: 2007
Tumor and Angiogenesis Research Group, Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece. targ@her.forthnet.gr
43. Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. Year Published: 2008
Harold Hopkins Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom.
44. Connexin specificity of second messenger permeation: real numbers at last. Year Published: 2008
Correspondence to aharris@umdnj.edu.
45. Connexin specificity of second messenger permeation: real numbers at last. Year Published: 2008
Department of Pharmacology and Physiology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA. aharris@umdnj.edu